🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Compound trial record
Trackers Drugs Trial finder
Compound · clinical trials

PD-1 inhibitor

Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 30 trials in our China and USA registers that name PD-1 inhibitor as an intervention. Synced 24 Sep 2026
30Trials tracked
19Recruiting now
16Lead sponsors
2Country registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov registry records · Last verified · Editorial standards

PD-1 inhibitor is named as a drug or biological intervention in 30 clinical trials in our China and USA trial registers, 19 of which are recruiting. Lead sponsors include Fudan University (4), The First Affiliated Hospital of Nanchang University (3) and Cancer Institute and Hospital, Chinese Academy of Medical Sciences (3). Registered phases: Phase 2, Phase 1/2, Phase 1, Not applicable, Phase 3, Observational, Phase EARLY_PHASE1 and Phase 2/3. Conditions studied include Advanced NSCLC; Nasopharyngeal Carcinoma; Neoadjuvant Therapy.

01

Clinical trials of PD-1 inhibitor

30 trials
NCT IDStudyPhaseStatusLead sponsorRegister
NCT05916248 Combination Therapy of Personalized mRNA-0217 Vaccines and Pembrolizumab in Patients With Advanced Solid Tumors (ClinicalTrials.gov ↗)
Advanced Solid Tumor
 Phase EARLY_PHASE1 Recruiting Ruijin Hospital China
NCT06496373 Clinical Study of mRNA Vaccine Combined With PD-1 Inhibitor as Adjuvant Therapy for Postoperative Pancreatic Cancer (ClinicalTrials.gov ↗)
Pancreatic Cancer Resectable, Chemotherapy-intolerant
 Phase EARLY_PHASE1 Recruiting Ruijin Hospital China
NCT04997837 Study of Adjuvant Chemotherapy With or Without PD-1 Inhibitors and Chemoradiotherapy in Resected pN3 Gastric (G) or GEJ Adenocarcinoma (ClinicalTrials.gov ↗)
Gastric Cancer
 Phase 3 Recruiting Fudan University China
NCT06086457 PD-1 Inhibitor Plus Chemotherapy With or Without Radiotherapy in Patients With Metastatic Esophageal Cancer (ClinicalTrials.gov ↗)
Esophageal Neoplasms
 Phase 3 Recruiting Cancer Institute and Hospital, Chinese Academy of Medical Sciences China
NCT06841679 Utidelone Capsule Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients With Gastric or Gastroesophageal Junction Adenocarcinoma
Gastric or Gastroesophageal Junction Adenocarcinoma
 Phase 2/3 Recruiting Beijing Biostar Pharmaceuticals Co., Ltd. USA, China
NCT05290194 Radiotherapy Combined With PD-1 Monoclonal Antibody and Capecitabine in the Treatment of Nasopharyngeal Carcinoma (ClinicalTrials.gov ↗)
Radiotherapy, PD-1 Inhibitor, Capecitabine
 Phase 2 Recruiting Fifth Affiliated Hospital, Sun Yat-Sen University China
NCT06281405 CAPOX and PD-1 Antibody Combined With or Without Radiotherapy for MSS Locally Advanced Rectal Cancer (ClinicalTrials.gov ↗)
Locally Advanced Rectal Cancer, Neoadjuvant Therapy
 Phase 2 Recruiting Fudan University China
NCT06751901 Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After Second-line Treatment (ClinicalTrials.gov ↗)
Advanced NSCLC
 Phase 2 Recruiting The First Affiliated Hospital of Nanchang University China
NCT06826079 Safety and Efficacy Study of Sorbitol With Neoadjuvant Chemotherapy Combined With Tirellizumab (PD-1 Inhibitor) in Patients With Locally Advanced Gastric Cancer (ClinicalTrials.gov ↗)
Gastric Junction Adenocarcinoma, Gastric Cancer, Immunotherapy
 Phase 2 Recruiting Union Hospital, Tongji Medical College, Huazhong University of Science and Technology China
NCT06977074 PROPHET Study: ctDNA-Guided Personalized Induction Immunochemotherapy for NSCLC (ClinicalTrials.gov ↗)
Non-small Cell Lung Cancer (NSCLC)
 Phase 2 Recruiting Sun Yat-sen University China
NCT07007182 Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer (ClinicalTrials.gov ↗)
Gastric Adenocarcinoma, Stomach Neoplasms
 Phase 2 Recruiting Jinbo Yue China
NCT07519486 Intensive Nutritional Support in Conversion Therapy for Locally Advanced Unresectable ESCC (ClinicalTrials.gov ↗)
Esophageal Squamous Cell Carcinoma, Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
 Phase 2 Recruiting Sichuan University China
NCT07072351 Hypofractionated Radiotherapy Combined With Immunochemotherapy for Conversion Treatment of Gastroesophageal Junction Adenocarcinoma (ClinicalTrials.gov ↗)
Gastroesophageal Junction Adenocarcinoma, Hypofractionated Radiotherapy, Immunotherapy
 Phase 1/2 Recruiting West China Hospital China
NCT07182565 Hypofractionated Radiotherapy Plus Immunochemotherapy for Neoadjuvant Treatment of Gastroesophageal Junction Adenocarcinoma (ClinicalTrials.gov ↗)
Gastroesophageal Junction Adenocarcinoma, Hypofractionated Radiotherapy
 Phase 1/2 Recruiting West China Hospital China
NCT07100405 TACE Combined With Anti-PD-1 Antibody in Patients With Advanced Hepatocellular Carcinoma: Study on Efficacy and Immune Microenvironment (ClinicalTrials.gov ↗)
Hepatocellular Carcinoma
 Observational Recruiting Fudan University China
NCT07618078 Real-World RAIRI-Guided Risk Stratification for Adjuvant Therapy Benefit After Chemoradiotherapy in NPC (ClinicalTrials.gov ↗)
Nasopharyngeal Carcinoma (NPC)
 Observational Recruiting Cancer Institute and Hospital, Chinese Academy of Medical Sciences China
NCT06622031 TIPS Combined With Lenvatinib and PD-1 Inhibitor for Advanced HCC With Main Trunk PVTT (ClinicalTrials.gov ↗)
Hepatocellular Carcinoma, Portal Vein Tumor Thrombus, Systemic Therapy
 Not applicable Recruiting Sun Yat-sen University China
NCT06752044 Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment (ClinicalTrials.gov ↗)
Advanced NSCLC
 Not applicable Recruiting The First Affiliated Hospital of Nanchang University China
NCT06752057 Neoantigen-loaded DC Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment (ClinicalTrials.gov ↗)
Advanced NSCLC
 Not applicable Recruiting The First Affiliated Hospital of Nanchang University China
NCT07551479 SCRT Based iTNT vs. LCRT Based TNT for MSS Locally Advanced Rectal Cancer (ClinicalTrials.gov ↗)
Locally Advanced Rectal Cancer (LARC), MSS (Microsatellite Stable)
 Phase 3 Not yet open Fudan University China
NCT06646666 ARTA-based Chemo-free Bridging/Maintenance Therapy in CAR-T Treatment for High-Risk R/R B-NHL Ineligible for HDCT and ASCT (ClinicalTrials.gov ↗)
B-cell Non Hodgkin Lymphoma
 Phase 2 Not yet open Ruijin Hospital China
NCT07417501 Lenvatinib Plus PD-1 Inhibitor for Advanced Solid Tumors With 11q13 Amplification (ClinicalTrials.gov ↗)
Solid Tumors
 Phase 2 Not yet open Tongji Hospital China
NCT07824856 Local Ablation Plus Systemic Therapy for Metachronous Liver and/or Lung Oligometastases From Nasopharyngeal Carcinoma (ClinicalTrials.gov ↗)
Nasopharyngeal Carcinoma, Neoplasm Metastasis, Lung Metastases
 Phase 2 Not yet open Sun Yat-sen University China
NCT07811076 Serine/Glycine-Restricted Diet With Chemoradiotherapy for Rectal Cancer (ClinicalTrials.gov ↗)
Locally Advanced Rectal Cancer (LARC)
 Phase 1/2 Not yet open Xuelei Ma MD China
NCT07154108 Endostatin Adenovirus With Checkpoint Inhibitor in Advanced Head and Neck or Esophageal Cancer (ClinicalTrials.gov ↗)
Esophageal Cancer, Head and Neck Cancer (H&Amp;Amp;Amp;N)
 Phase 1 Not yet open Sichuan University China
NCT05340270 PD-1 Inhibitor Plus GP as Neoadjuvant Therapy for Locoregionally Advanced Nasopharyngeal Carcinoma (ClinicalTrials.gov ↗)
Nasopharyngeal Carcinoma, Neoadjuvant Therapy, PD-1 Inhibitor
 Phase 2 Active, closed Guangxi Medical University China
NCT07791602 Induction Chemoimmunotherapy Followed by Deescalated Definitive Radiotherapy in Head and Neck Cancer (ClinicalTrials.gov ↗)
Head and Neck Squamous Cell Carcinoma, Locally Advanced Head and Neck Cancer, HNSCC
 Phase 2 Active, closed Cancer Institute and Hospital, Chinese Academy of Medical Sciences China
NCT06710847 A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors (ClinicalTrials.gov ↗)
Neoplasms, Colorectal, Solid Tumor, Colon Cancer
 Phase 1/2 Active, closed GlaxoSmithKline USA
NCT04947241 Toripalimab Combined With Gemcitabine and Cisplatin Treating Resectable Locally Advanced HNSCC (ClinicalTrials.gov ↗)
Locally Advanced Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy
 Phase 1 Active, closed Fifth Affiliated Hospital, Sun Yat-Sen University China
NCT05338775 A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma (ClinicalTrials.gov ↗)
Relapsed/ Refractory Multiple Myeloma
 Phase 1 Active, closed Janssen Research & Development, LLC USA

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

02

Conditions studied

46 conditions
Condition (as registered)Trials
Advanced NSCLC3
Nasopharyngeal Carcinoma3
Neoadjuvant Therapy3
Gastric Cancer2
Immunotherapy2
Hepatocellular Carcinoma2
Gastroesophageal Junction Adenocarcinoma2
Hypofractionated Radiotherapy2
PD-1 Inhibitor2
Locally Advanced Rectal Cancer (LARC)2
Gastric or Gastroesophageal Junction Adenocarcinoma1
Neoplasms, Colorectal1
Solid Tumor1
Colon Cancer1
Rectal Cancer1
Relapsed/ Refractory Multiple Myeloma1
Nasopharyngeal Carcinoma (NPC)1
Gastric Junction Adenocarcinoma1
Neoadjuvant Therapies1
Esophageal Cancer1
Head and Neck Cancer (H&Amp;Amp;Amp;N)1
Portal Vein Tumor Thrombus1
Systemic Therapy1
Non-small Cell Lung Cancer (NSCLC)1
Chemotherapy1
Esophageal Neoplasms1
Esophageal Squamous Cell Carcinoma1
Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma1
Radiotherapy1
Capecitabine1
Solid Tumors1
Locally Advanced Rectal Cancer1
Gastric Adenocarcinoma1
Stomach Neoplasms1
B-cell Non Hodgkin Lymphoma1
Neoplasm Metastasis1
Lung Metastases1
Liver Metastases1
Head and Neck Squamous Cell Carcinoma1
Locally Advanced Head and Neck Cancer1

+ 6 more conditions in the trial records above.

03

Sponsors

lead sponsor per trial
Lead sponsorTrials
Fudan University4
The First Affiliated Hospital of Nanchang University3
Cancer Institute and Hospital, Chinese Academy of Medical Sciences3
Sun Yat-sen University3
Ruijin Hospital3
Sichuan University2
West China Hospital2
Fifth Affiliated Hospital, Sun Yat-Sen University2
Beijing Biostar Pharmaceuticals Co., Ltd.1
GlaxoSmithKline1
Janssen Research & Development, LLC1
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology1
Tongji Hospital1
Jinbo Yue1
Xuelei Ma MD1
Guangxi Medical University1
04

Trials by country register

RegisterPD-1 inhibitor trials
Clinical trials in China28
Clinical trials in USA3

A trial with sites in more than one country appears in each of those registers.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how PD-1 inhibitor works or whether it is effective. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists PD-1 inhibitor (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.